TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04360824
Drug: Intermediate dose thromboprophylaxis
Normalized name: Prevotella intermedia
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2) Patients randomized to the intervention arm will receive intermediate-dose enoxaparin (1 mg/kg Subcutaneously daily if BMI\<30kg/m2 or 0.5 mg/kg Subcutaneously twice daily if BMI ≥ 30kg/m2).
Study: NCT04360824
Drug: Standard of Care thromboprophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomized to the standard of care arm will receive standard prophylactic dose enoxaparin (40 mg subcutaneously daily if BMI \<30kg/m2 and 30 mg subcutaneously twice daily or 40 mg subcutaneously twice daily if BMI ≥ 30 kg/m2).
Study: NCT00304070
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01049880
Drug: Gemcitabine with escalating ascorbic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine (1000 mg/m2) weekly for three weeks and then one week off. Ascorbic acid, given twice weekly, escalating doses weekly. Week 1: 15 grams ascorbic acid per infusion Week 2: 25 grams ascorbic acid per infusion Week 3: 50 grams ascorbic acid per infusion Week 4: 75 grams ascorbic acid per infusion Week 5: 100 grams ascorbic acid per infusion~Ascorbic acid infusion dose is maintained at the level that provides a serum level of 350-400 mg/dL.
Study: NCT01223079
Drug: r-hFSH and r-hLH
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will begin r-hLH at 300IU/day when there are 2 follicles greater than or equal to 14mm.
Study: NCT00377676
Drug: Usual Diabetes Therapy plus placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet taken orally once in the morning, beginning with one tablet daily, titrated up by 1 tablet each week to a maximum of 6 tablets daily
Study: NCT03586999
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dosage calculations will be based on the patient's body surface area (BSA) at baseline, recommend using the Mosteller formula and administered through IV. Dose adjustments at the beginning of each cycle do not need to be made unless there has been a \>10% weight gain or loss. Patients receive six 21-day cycles of the medications.
Study: NCT03586999
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dosage calculations will be based on the patient's body surface area (BSA) at baseline, recommend using the Mosteller formula and administered through IV. Dose adjustments at the beginning of each cycle do not need to be made unless there has been a \>10% weight gain or loss. Patients receive six 21-day cycles of the medications.
Study: NCT01831687
Drug: Etodolac Extended Release Tablets USP 600mg
Normalized name: etodolac Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etodolac Extended Release Tablets USP 600mg once a day
Study: NCT01831687
Drug: Etodolac Extended Release Tablets 600mg
Normalized name: etodolac Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etodolac Extended Release Tablets 600mg once a day
Study: NCT03735420
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo (vehicle) will be administered in a capsule. Participants in the placebo arm will consume the capsule once per day, with the first meal.
Study: NCT04456699
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg/m\^2 oral capsule BID for 14 days, then 7 days off, Q3W) until progressive disease or end of study
Study: NCT04456699
Drug: Leucovorin/ levoleucovorin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg/m\^2 (leucovorin) or 200 mg/m\^2 (levoleucovorin) may be added to Bevacizumab + 5-FU per investigator's discretion Q2W IV infusion until progressive disease or end of study
Study: NCT03806452
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets of 100 and 1000 mg to mimic hydroxycarbamide tablets
Study: NCT02842268
Drug: BAY987517
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test product dried for at least 15 minutes.Subjects to ride for 30 minutes on a stationary bicycle.(Formulation Number :Y73-161)
Study: NCT04002674
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thirty (30) patients in arm 1 will receive the matching placebo (sugar pill) one (1) capsule orally (without food) once daily for 6 months (180 days).
Study: NCT02354638
Drug: Pharmacotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy will also be prescribed as per the need assessment consisting of:~Nicotine Chewing Gums:~Dose: 2 mg/4 mg, 10-15 pieces per day with maximum dose of 24 pieces/day depending on cravings.Total Duration: 12 weeks Duration of treatment: Higher dose for 4-6 weeks, with weaning till 2-3 months~Nicotine Transdermal patches:~Dose: 7 mg/10 mg/14 mg/21 mg -for 24-hours use. Total Duration: 12 weeks Duration of treatment: Higher strength patch for 2 weeks and depending on cravings will be gradually decreased till 4 weeks
Study: NCT00434096
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration once daily
Study: NCT00024518
Drug: 30,000 units hrINF-alpha
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00024518
Drug: 5,000 hrINF-alpha
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02822794
Drug: SOF/VEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400/100 mg tablet administered orally once daily
Study: NCT01144338
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection, matching volume of placebo, administered once weekly.
Study: NCT01459796
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo loading dose followed by placebo injections (2 mL) qw for 52 weeks.
Study: NCT02170727
Drug: DCV/ASV/BMS-791325
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03143244
Drug: Ketorolac-Midazolam group (KM)
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients received 0.5mg/kg ketolac in 50 ml saline over 10 min before induction and 25ug/kg midazolam in 50 ml saline over 10 min i.v 30 min before induction then 50ug/kg/h of ketolac and 40ug/kg/h midazolam till end of surgery in two separate syringe pumps.
Study: NCT03143244
Drug: Control group (Normal Saline) (C)
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients received normal saline in two sets
Study: NCT03231371
Drug: Adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of intravenous adenosine infusion over 3 minutes (0.14 ml/kg, 3mg/ml concentration, total dose).
Study: NCT01921972
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be similar in appearance to Memantine
Study: NCT01170897
Drug: PEGPH20
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEGylated Recombinant Human Hyaluronidase
Study: NCT02317640
Drug: Testosterone Gel applied by a pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: After being diagnosed with low testosterone levels the participant will be given a 30-day supply of the Testosterone/placebo gel (40.5 mg/day). The gel is to be applied every morning on clean and dry area of skin of the upper arms and shoulders.
Study: NCT02604589
Drug: bupivicaine 0.25%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Dose analgesia
Study: NCT02604589
Drug: bupivicaine 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose analgesia
Study: NCT04249544
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1mg equivalent of placebo
Study: NCT02442700
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment B = administration placebo for 12 weeks
Study: NCT00906308
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PO (orally) matched placebo (administered twice a day, BID) for up to 12 weeks
Study: NCT02621905
Drug: Lozanoc
Approvals — FDA: no, EMA: no, PMDA: no
Description: At least 2 capsules twice a day for 3 weeks
Study: NCT00142909
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lofexidine Placebo
Study: NCT02741947
Drug: Levodopa Benserazide Madopar
Normalized name: benserazide / levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Madopar 100+25mg and 200+50mg, tablet, tid e qid, for four weeks
Study: NCT02741947
Drug: Levodopa Benserazide Teva Italia
Normalized name: benserazide / levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa benserazide Teva 100+25mg and 200+50mg, tablet, tid e qid, for four weeks
Study: NCT02563041
Drug: 30% TSC
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients were randomly assigned to have their catheter locked with either unfractionated sodium heparin 5000 U/mL or 30% trisodium citrate.
Study: NCT02563041
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patients were randomly assigned to have their catheter locked with either unfractionated sodium heparin 5000 U/mL or 30% trisodium citrate.
Study: NCT04523129
Drug: CyclASol topical ocular, eye drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine A solution in vehicle
Study: NCT04523129
Drug: Vehicle topical ocular, eye drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle
Study: NCT00578370
Drug: Ciclosporin 0.5% (Formulation 01B)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cutaneous emulsion 200µl once a day (26 days)
Study: NCT00578370
Drug: Ciclosporin 1.5% (Formulation 02B)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cutaneous emulsion 200µl once a day (26 days)
Study: NCT00578370
Drug: Formulation 00B
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cutaneous emulsion (Vehicle to Formulation 01B and Formulation 02B) 200µl once a day (26 days)
Study: NCT02090907
Drug: Levothyroxine
Normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02090907
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03096782
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02139644
Drug: FS MDPI
Normalized name: Derma-Smoothe FS
Approvals — FDA: no, EMA: no, PMDA: no
Description: FS MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate (Fp) and salmeterol xinafoate (Sx) dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened.~During the treatment period, participants were randomized to either 100/12.5 mcg Fp/Sx or 50/12.5 mcg Fp/Sx in the morning and evening for a total daily dose of 200/25 mcg or 100/25 mcg Fp/Sx.~Participants were instructed to rinse their mouth and expectorate (not swallow) after study drug administration.
Study: NCT02139644
Drug: Placebo MDPI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered via a multidose dry powder inhaler (MDPI) one puff in the morning and one puff in the evening for 12 weeks.
Study: NCT00745732
Drug: ZD6474 (ZACTIMA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZD6474 (ZACTIMA) beginning at 100 mg once a day by mouth
Study: NCT00352534
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01179594
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally daily, 24 weeks (weeks 12-36)
Study: NCT03412643
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60 mg/m2 IV Day 1 every 2 weeks or 3 weeks at investigator's discretion for a total of 4 cycles
Study: NCT03412643
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 600 mg/m2 IV Day 1 every 2 weeks or 3 weeks at investigator's discretion for a total of 4 cycles
Study: NCT00388518
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: po daily
Study: NCT02376452
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400mg/m2 iv gtt,d1
Study: NCT01449448
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subacromial injection
Study: NCT02684591
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00414752
Drug: AFQ065
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02182544
Drug: WAL801CL dry syrup
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02182544
Drug: WAL 801 CL dry syrup placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00279123
Drug: no treatment
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01160107
Drug: RP followed by MPR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction (4 cycles):Lenalidomide 25 mg/die for 21 days followed by a 7 days rest period and Prednisone at 50 mg three times a week continuously . Consolidation (6 cycles): Melphalan 2 mg three times a week, Prednisone 50 mg three times a week, and Lenalidomide 15 mg/die for 21 days followed by a 7 days rest period. According to the results of the first stage the decisions are as follows: 1. Starting a second stage, at the same dose of lenalidomide for MPR cycles, if grade 3-4 adverse events are 25-50% and PR \> 50%; 2. The study stop (if PR \<40% and grade 3-4 adverse events \>25-30%) 3. A new first stage may be started: - Lenalidomide 20 mg/die if grade 3-4 adverse events are \< 25-30%, independently from efficacy; - Lenalidomide 10 mg/die if grade 3-4 adverse events are \> 50% and PR rate \> 50%. Maintenance: Lenalidomide 10 mg/day from day 1 to 21, followed by a 7-day rest period and Prednisone 25 mg three times a week.Each cycle will be repeated every 28 days, until PD.
Study: NCT02082522
Drug: Photodynamic therapy-Photofrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) involves the i.v. injection of Photofrin (2 mg/kg) followed by the illumination of the tumor using a fiber optic device during an endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous transhepatic cholangiography (PTC). Two days after the injection, a laser light (180 J/cm(2)) will be applied to the tumor. A second light application will be given 96-120 hours after Photofrin injection if PDT could not initially be performed on all sides of the tumor. Post illumination, all patients will undergo stenting as part of standard medical care procedure. Up to 3 additional courses of PDT using a light dose of 120 J/cm(2) may be given at 3-month intervals.
Study: NCT02082522
Drug: Chemotherapy regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: The regimen will comprise gemcitabine (1 000 mg/m(2)) followed by cisplatin (25 mg/m(2)), each administered on days 1 and 8 every 3 weeks (21 day-cycle) for four cycles. An additional 12 weeks of the same chemotherapy regimen may be administered if there is no disease progression or intolerable toxicity.
Study: NCT03511521
Drug: NPH Insulin
Normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate acting insulin
Study: NCT00440271
Drug: Optimized Background Regimen (OBR)
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients received between two and four active anti-retroviral medications based on resistance testing results, as background treatment, and remained on these for the duration of the trial.
Study: NCT02978144
Drug: AxV-128/Tc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of AxV-128 labeled with 99mTc
Study: NCT04239846
Drug: AC-701 Topical Gel 0.3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: AC-701 Topical Gel 0.3%, BID
Study: NCT00685815
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250cc NS IV over one hour, once on Day 3, once on Day 4
Study: NCT00838305
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: drug: placebo subjects also get citalopram and placebo in a 2x2 crossover design
Study: NCT02112097
Drug: Adverse Reactions of Enbrel subcutaneously
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adverse Reactions of Enbrel subcutaneously at Week 36, in number of Injection site reactions, Heart failure, Allergic Reactions, Blood problems/low blood counts, Nervous system, Infections, Malignancies, Immunogenicity, and Autoantibodies.
Study: NCT02112097
Drug: Adverse Reactions of Enbrel subdermally at Week 36
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adverse Reactions of Enbrel subdermally at Week 36, in number of Injection site reactions, Heart failure, Allergic Reactions, Blood problems/low blood counts, Nervous system, Infections, Malignancies, Immunogenicity, and Autoantibodies.
Study: NCT03616418
Drug: antiplatelet drugs;statins;antihypertensive drugs
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00000415
Drug: Calcium supplement
Normalized name: Calcium supplement
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01495962
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (Normal Saline)
Study: NCT02896231
Drug: PLB1001
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLB1001 is a capsule in the form of 25 mg and 100mg, twice daily.
Study: NCT03333005
Drug: APX001 with Standard of Care anti-fungal agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: safety assessment
Study: NCT02039427
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ketorolac 30 mg mixed with normal saline 1 ml : total volume of 2 ml
Study: NCT02039427
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 2 ml
Study: NCT02875119
Drug: Griffithsin Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Griffithsin Gel is a large biologic molecule that is intended for vaginal rather than systemic administration. In addition, Griffithsin Gel is being developed for the prevention of HIV infection and not as a therapeutic agent. The concentration of Griffithsin Gel associated with prevention of HIV in vitro and in vivo has been established in non-clinical studies (see Section 5). Studies have demonstrated that Griffithsin Gel is highly potent for HIV prevention and is effective at very low concentrations.~One 4 mL dose of PC-6500, designed to provide an adequate vaginal concentration of GRFT for the prevention of HIV, based on preclinical data, will be evaluated. Rising dose tolerance is not the goal of this study because GRFT is likely to be minimally absorbed systemically, if at all.
Study: NCT02875119
Drug: Placebo Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Gel
Study: NCT00510029
Drug: GAP-134
Normalized name: GAP JUNCTION ALPHA-3 PROTEIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: atrial fibrillation 24-hr IV infusion; 1-minute IV bolus; PO
Study: NCT00399438
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets, Oral, once daily, 2 weeks
Study: NCT03264157
Drug: HRIG
Normalized name: Human Rabies Immune Globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: A 20 IU/kg dose of BPL HRIG will be given on Day 0 via IM injection.
Study: NCT00506935
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT01358981
Drug: LY2881835
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT01358981
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT00550784
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02973659
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03813303
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administration of fentanyl by anesthesiologist for sedation.
Study: NCT02174094
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04574362
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT03055234
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo for TID administration
Study: NCT00575588
Drug: Sulphonylurea
Normalized name: metformin and sulfonylureas
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glipizide 5-20 mg capsules (titrated to optimal effect or highest tolerable dose during 18 weeks)
Study: NCT00585754
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT00614939
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00000463
Drug: lovastatin
Normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03650205
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral capsule.
Study: NCT03149640
Drug: Inhaled amikacin
Normalized name: amikacin Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once a day, inhaled amikacin at day 4, day 5 and day 6 of invasive mechanical ventilation: 20 mg/kg of ideal body weight, maximum 2 g per day.
Study: NCT03149640
Drug: Inhaled placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once a day, inhaled placebo at day 4, day 5 and day 6 of invasive mechanical ventilation.
Study: NCT01961830
Drug: ME1100 inhalation solution
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00286143
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl is added to epidural Bupivacaine to be administered to neonates having thoracotomy for lung resections.
Study: NCT03029208
Drug: Iron therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron therapy will be administered if ferritin is \<=100 ng/mL and/or TSAT is \<=20%.
Study: NCT01700946
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: given intravenously
Study: NCT01700946
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: given intrathecally or intravenously
Study: NCT01700946
Drug: mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: given orally
Study: NCT01700946
Drug: therapeutic hydrocortisone
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: given intrathecally